1. Phase 3 trial of toripalimab in nasopharyngeal carcinoma.
2. Median follow-up: 37 months.
3. 3-year FFS: 88.3% (cisplatin-sparing) vs 87.6% (standard).
4. Fewer adverse events in cisplatin-sparing group.
5. 532 patients enrolled across 13 hospitals in China.
6. Limitations: patient demographics and lack of long-term toxicity data.
7. Future trials assess PD-1 blockade combinations.

Source: JAMA